Phase I Safety Trial of HIV Antibody P2G12

Phase 1, randomised, single-blind trial of P2G12 in human immunodeficiency virus infection (HIV) (3 cohorts), sponsored by St George's, University of London. Primary endpoints: Number of participants with treatment-related adverse events and serious adverse events at 3 months and Number of participants with local and systemic reactogenicity signs and symptoms post-infusion at 3 months. Status: unknown.